MHRA on Senokot
This article was originally published in The Tan Sheet
A Senokot Hi-Fiber TV ad claiming consumers can take the product to "top up" their daily fiber intake in order to stay regular will be withdrawn because it is in breach of UK advertising legislation, the Medicines & Healthcare products Regulatory Agency says May 23. Senokot is "for the relief of constipation" and is "not indicated for maintenance of regularity per se in the general healthy population," MHRA explains...
You may also be interested in...
US FDA looks to post-marketing studies to address elements of the NDA that were not central to its initial swift approval as the first COVID-19 therapy, including pediatric use and the interaction of hepatotoxicity and dose duration.
But advisory committee members caution against including pediatric population in COVID-19 vaccine trials, and one member expresses concern that Pfizer is testing those as young as 12 years of age. Agency is in discussions with product sponsors about enrollment of adolescents.
Public Company Edition: Four health care special purpose acquisition vehicles went public and two others announced mergers, but only one biopharma firm priced an IPO during the week of 19-23 October. Replimune’s $250m offering led recent FOPOs.